Is Pacific Biosciences of California (PAC) stock a good buy?
Pacific Biosciences of California has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings. According to analysts' consensus price target of $51.67, Pacific Biosciences of California has a forecasted upside of 222.5% from its current price of $16.02.
Where can I buy PACB shares?
Shares of PACB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Which stocks are quantitatively similar to PACB?
Stocks that are quantitatively similar to PACB, based on their financial statements, market capitalization, and price volatility, are BOX, VUZI, RAMP, FROG, and GH. Visit PACB's SEC page to see the company's official filings. To visit the company's web site, go to www.pacb.com.
When is Pacific Biosciences of California expected to release its quarterly earnings?
Pacific Biosciences of California is scheduled to release its next quarterly earnings announcement on Wednesday, February 9th 2022. View our earnings forecast for Pacific Biosciences of California. How were Pacific Biosciences of California's earnings last quarter?
Is Pacb a good stock to buy?
Pacific Biosciences of California has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Why is Pacb stock dropping?
PacBio stock is falling today because the company reported unaudited fourth-quarter revenue that reached just $36 million. Image source: Getty Images. Compared to the prior-year period, revenue soared 33%.
Is Pacb a buy Zacks?
The Zacks database contains over 10,000 stocks. All of those stocks are classified into three groups: Sector, M Industry and X Industry....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return1Strong Buy24.75%2Buy18.15%3Hold9.70%4Sell5.35%2 more rows
What does Pacific Biosciences of California do?
About Pacific Biosciences of California Inc Pacific Biosciences of California, Inc. is a life science technology company. The Company designs, develops and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems.
Will Pacb stock go up?
Stock Price Forecast The 6 analysts offering 12-month price forecasts for Pacific Biosciences of California Inc have a median target of 16.50, with a high estimate of 27.00 and a low estimate of 6.00. The median estimate represents a +269.96% increase from the last price of 4.46.
Who bought Pacific Biosciences?
Illumina, Inc.On 1 November 2018, Illumina, Inc. agreed to purchase PacBio for US$1.2 billion in cash. The deal was expected to close in the fourth quarter of 2019.
What is next generation sequencing technology?
Next-generation sequencing (NGS) is a massively parallel sequencing technology that offers ultra-high throughput, scalability, and speed. The technology is used to determine the order of nucleotides in entire genomes or targeted regions of DNA or RNA.
How many employees does Pacific Biosciences have?
Pacific Biosciences corporate office is located in 1305 O'brien Dr, Menlo Park, California, 94025, United States and has 665 employees.
How many employees does PacBio have?
728Pacific Biosciences / Number of employees (Dec 2021)
Should I buy or sell Pacific Biosciences of California stock right now?
4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last year. There are cur...
What is Pacific Biosciences of California's stock price forecast for 2022?
4 brokerages have issued 1 year price targets for Pacific Biosciences of California's shares. Their forecasts range from $6.00 to $41.00. On averag...
How has Pacific Biosciences of California's stock performed in 2022?
Pacific Biosciences of California's stock was trading at $20.46 on January 1st, 2022. Since then, PACB shares have decreased by 79.1% and is now tr...
When is Pacific Biosciences of California's next earnings date?
Pacific Biosciences of California is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022. View our earnings...
How were Pacific Biosciences of California's earnings last quarter?
Pacific Biosciences of California, Inc. (NASDAQ:PACB) released its quarterly earnings results on Wednesday, May, 4th. The biotechnology company rep...
Who are Pacific Biosciences of California's key executives?
Pacific Biosciences of California's management team includes the following people: Mr. Christian O. Henry M.B.A. , Pres, CEO & Director (Age 54,...
What is Christian Henry's approval rating as Pacific Biosciences of California's CEO?
2 employees have rated Pacific Biosciences of California CEO Christian Henry on Glassdoor.com . Christian Henry has an approval rating of 100% amo...
Who are some of Pacific Biosciences of California's key competitors?
Some companies that are related to Pacific Biosciences of California include Thermo Fisher Scientific (TMO) , Agilent Technologies (A) , Illumin...
What other stocks do shareholders of Pacific Biosciences of California own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Pacific Biosciences of California investors own include Pf...
Is Pacific Biosciences of California stock a Buy, Sell or Hold?
Pacific Biosciences of California stock has received a consensus rating of hold. The average rating score is and is based on 5 buy ratings, 6 hold...
What was the 52-week low for Pacific Biosciences of California stock?
The low in the last 52 weeks of Pacific Biosciences of California stock was 4.49. According to the current price, Pacific Biosciences of California...
What was the 52-week high for Pacific Biosciences of California stock?
The high in the last 52 weeks of Pacific Biosciences of California stock was 36.33. According to the current price, Pacific Biosciences of Californ...
What are analysts forecasts for Pacific Biosciences of California stock?
The 11 analysts offering price forecasts for Pacific Biosciences of California have a median target of 26.27, with a high estimate of 52.00 and a l...
Recently Viewed Tickers
Pacific Biosciences of California Inc
Visit a quote page and your recently viewed tickers will be displayed here.
How much money does Pacific Biosciences make?
Pacific Biosciences of California, Inc. engages in the development, manufacture and sale of an integrated platform for genetic analysis. The firm's products and services include PacBio sequel system, consumables, analytical software and single molecule real-time (SMRT) compatible products.
When is Pacific Biosciences' next earnings announcement?
How much money does Pacific Biosciences of California make? Pacific Biosciences of California has a market capitalization of $5.89 billion and generates $78.89 million in revenue each year. The biotechnology company earns $29.40 million in net income (profit) each year or ($0.43) on an earnings per share basis.
What is the symbol for Pacific Biosciences?
When is Pacific Biosciences of California's next earnings date? Pacific Biosciences of California is scheduled to release its next quarterly earnings announcement on Monday, August 2nd 2021. View our earnings forecast for Pacific Biosciences of California.
Where is Pacific Biosciences located?
What is Pacific Biosciences of California's stock symbol? Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB.".
Content From Our Affiliates
Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-521-8000 or via email at [email protected].
Profile
Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems.
What is market capitalization for companies?
Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems.
How to calculate restricted stock?
For companies with multiple common share classes, market capitalization includes both classes. Shares Outstanding. Number of shares that are currently held by investors, including restricted shares owned by the company's officers and insiders as well as those held by the public. Public Float.
Component Grades
To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded. A company's dividend expressed as a percentage of its current stock price.
PACB POWR Grades
We have 9 different ratings for every stock to help you appreciate its future potential. You can unlock it all now.
PACB Stock Summary
PACB scores best on the Growth dimension, with a Growth rank ahead of 53.4% of US stocks.
PACB Valuation Summary
PACB's price/sales ratio is 20.8; that's higher than the P/S ratio of 93.05% of US stocks.
PACB's Quality Factors
PACB's price/sales ratio is 58.9; this is 1450% higher than that of the median Healthcare stock.
Latest PACB News From Around the Web
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
Continue Researching PACB
Below are the latest news stories about Pacific Biosciences Of California Inc that investors may wish to consider to help them evaluate PACB as an investment opportunity.
Transparency is our policy. Learn how it impacts everything we do
Want to see what other sources are saying about Pacific Biosciences Of California Inc's financials and stock price? Try the links below:
How we make money
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
How we use your personal data
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management.
How we approach editorial content
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
